Fetal rhabdomyomatous nephroblastoma is a weird variant of Wilms tumor. It's a chemo-resistant tumor, characterized for invading the collecting system, and having greater rates of bilateral involvement. The tumor chiefly consists of fetal striated muscle with particularly distinct striations and central nuclei, and isolated regions of typical trimorphic nephroblastoma. The following article brings in a new case of this rare pathology, associated with a review of the literature
Introduction
Fetal rhabdomyomatous nephroblastoma (FRN) is a weird variant of Wilms tumor (WT), first described by Eberth in 1872 as "myoma sarcomatodes renum". The tumour chiefly consists of fetal striated muscle with particularly distinct striations and central nuclei, and isolated regions of typical trimorphic nephroblastoma. It is a chemoresistant tumor, characterized by invading the collecting system, and having greater rates of bilateral involvement [1] [2] [3] [4] [5] [6] [7] [8] [9] . The following article brings the principal clinic, therapeutic and evolutive characteristics in a new case of this rare pathology and a review of the literature.
Case report 23-month-old girl with a palpable abdominal mass of a month of evolution. On physical examination, the patient was in good general conditions, adequate weight and height for age. A large firm mass was palpated in the right flank, associated with collateral circulation and hepatomegaly, extending to the left hypochondrium. Abdominal ultrasonography showed a solid mass of 125x128x110 mm replacing the right kidney. Contrast enhanced thoraco-abdominal computed tomography (CT) showed a right kidney lesion of 135x130x128 mm, suggestive of WT, with anterior displacement of the right PEDIATRIC UROLOGY CASE REPORTS Elevated blood pressure was found, with diagnosis of state 2 hypertension, without vital organs compromised. Amlodipine, clonidine and captopril were indicated. An abdominal mass suggestive of WT as a first option was considered, but a neuroblastoma was also considered because of the early appearance. Taking into account the possible metastatic disease in the lung, the size of the lesion, the involvement of near structures, and the high risk of intraoperative tumoral rupture, neoadjuvant chemotherapy was initiated, with the following protocol: PET scan was done 2 months after surgery, without finding lesions that suggested the presence of tumoral disease. Expectant management was decided.
Discussion FRN is a monophasic mesenchymal variant of WT [1] , with an estimated prevalence of 1.5-4.5%. It's bilateral in 30% of cases. Local relapses and the presence of metastatic disease imply a worse prognosis. This tumor doesn't respond well to chemotherapy protocols (because of its mesenchymal component: fetal rhabdomyomatous tissue) [2] . Wigger [1] first used the term fetal rabdomyomatous nephroblastoma in 1976. It is microscopically characterized by striated muscle with different striations and central nuclei. The histology of this muscle reminds that to fetal striated muscle, and it's accompanied by undifferentiated tissue areas, neoplastic epithelium and mesenchymal components, such as adipose and myxoid tissue, and cartilage islands. It is microscopically and macroscopically similar to congenital mesoblastic nephroma, and the only difference is quantitative, because in this one there is a predomination of smooth muscle, while in FRN the presence of striated muscle fibers predominates [3] . Nonetheless, congenital mesoblastic nephroma has unique characteristics, as it is considered the most common solid tumor of the newborn, usually identified in the first 3 months of life. It's origin is given by proliferation of early nephrogenic mesenchymal tissue with monomorphic histology, mesenchymal cells proliferations, and embrionary metaplasm soaked in normal renal tissue. It's usually benign, with complete healing after a nephrectomy with wide margins [4] . It's known that FRN is usually of greater size than WT, but its behavior in a complete resection scenario is less aggressive. There is an important difference in the age of presentation, according to Wigger, FRN predominates in 1-year-old [1] , and WT presents in patients of 2-3 years old. There aren't reported cases in patients older than 4 years old. Beckwit et al. [5] described that the clinical behavior of nephroblastoma is defined by the aggressiveness of the tumor. A blastomatous predominant WT is associated with a high aggressiveness pattern (76% of cases in 3-4 stage), but due to its good answer to chemotherapy, free disease survival rates are high. FRN is usually diagnosed in early stages (80%), but it is chemo resistant, so patients present low survival rates if the tumor is not totally resected. Pollono [6] described a 14 patient's cohort diagnosed with FRN, with a mean age of 27 months, and a bilateral presentation of 22%. After cytoreduction and adjuvant therapy, only 6 patients were free of disease, and 8 had died. The same findings were reported by Saba [7] , and Maes et al [8] , whom noted poor survival rates in patients with FRN taken into incomplete resection of the tumor. Anderson proposed the hypothesis that a poor response to chemotherapy in patients with bilateral WT was associated with post chemotherapy presence of rhabdomyomatous histology [9] . He demonstrated a significant association between post chemotherapy rhabdomyomatous differentiation and poor radiologic answer. Tumor size has been employed as a prognosis indicator, due to the fact that in classic nephroblastoma, it is inversely related with survival rates [10, 11] . Some authors have described that volumes greater than 551 cc, survival rates are close to zero. Maes found a mean volume of 965 cc (17.3 to 2520 cc) in patients with FRN [8] . However, the mean survival rate in these patients was of 4 years. There is no way to differentiate FRN from classic WT in initial studies. Nonetheless, it is important to emphasize that initial study of an abdominal mass is done with ultrasonography. When solid lesions suggestive of malignant disease are found, a contrast-enhanced CT must be done, because of its greater sensibility for establishing vascular, local and lymphatic extension [12] . Magnetic resonance is the imaging study of choice to determine vascular involvement [12] . Conclusions FRN is a variant of WT, with better prognosis when local control is adequate. Diagnosis is histological.
It responds poorly to chemotherapy, so an aggressive resection is important to achieve greater survival rates.
